SEARCH WITHIN CONTENT
VOLUME 3 , ISSUE 2 ( July-December, 2013 ) > List of Articles
Aracelys Blanco, Heidy Trujillo, Dunia Hernández, Daymir García, Yadira Lobaina, Freya Freyre, Nelson Merino, Jose Suarez
Citation Information : Blanco A, Trujillo H, Hernández D, García D, Lobaina Y, Freyre F, Merino N, Suarez J. The Adoptive Transfer of HBsAG-specific Splenocytes from Balb/c Congenic Donors into HBsAg Transgenic Mice is not associated to Histographological Damage. Euroasian J Hepatogastroenterol 2013; 3 (2):97-102.
License: CC BY-NC 4.0
Published Online: 01-12-2017
Copyright Statement: Copyright Â© 2013; The Author(s).
Background: Hepatitis B virus (HBV) infections remain as a major health problem. It has been estimated that about 370 million people are chronically infected worldwide. Chronic infection also increases the risk of liver diseases such as cirrhosis and hepatocellular carcinoma. Current antiviral therapies fail to control viral replication in the long term. Viral persistence has cellular immunity. The limitations of the current available therapies underline the need for alternative therapies. The development of a HBV therapeutic vaccine still remains as a feasible option of treatment despite several drawbacks. Recently, approaches like adoptive T-cell therapy have been evaluated. Materials and methods: The adoptive transfer was done intraperitoneally using Balb/c mice as donors and HBsAg- IgG response and biochemical parameters was evaluated in transgenic mice sera by ELISA. The histopathological analysis of the main organs was carried out. Results and discussion: In the present work we demonstrated ! cause histopathological damage. The potent immune response transferred was developed in non-Tg Balb/c mice after multiple simultaneous intranasal and subcutaneous immunizations with NASVAC, a novel HBV therapeutic vaccine candidate. The results indicated that the transference of immunity is safe and also capable of transiently reducing the HBsAg concentration in the sera of transgenic mice. These data support the safety of the therapeutic vaccination using NASVAC and also are in line with the usefulness of the T-cell therapy for chronic hepatitis B.